Important Notice for MoonLake Immunotherapeutics Investors
In a significant development for investors in MoonLake Immunotherapeutics (NASDAQ: MLTX), the esteemed legal firm Hagens Berman is actively advising those who have invested in the company about the approaching Lead Plaintiff Deadline in the securities class action lawsuit against the firm. It is crucial for investors to understand their options and take appropriate actions before the deadline.
Details of the Lawsuit
The lawsuit brings forward serious allegations against MoonLake and select executives, claiming they made materially misleading statements concerning the clinical potential of their primary drug candidate, sonelokimab (SLK). The fallout from these misleading statements has been severe, leading to a catastrophic drop in the stock value, which fell nearly 90% following the announcement of less-than-anticipated results from Phase 3 clinical trials.
The Core Allegation of the Case
At the center of this lawsuit is the assertion that MoonLake's representations regarding SLK’s distinct Nanobody structure, which they touted as a breakthrough offering superior clinical outcomes over traditional monoclonal antibodies, were not substantiated by the results of the clinical trials. Investors expected promising efficacy results but were faced with disappointing news, leading to significant financial loss.
Statement from Hagens Berman
Reed Kathrein, a partner at Hagens Berman managing this case, expressed the firm's determination to hold MoonLake accountable. 'The continuous assurances provided by the company regarding the perceived superiority of their Nanobody technology have resulted in widespread frustration and loss for investors. As the deadline of December 15 approaches, we urge affected investors to contact our firm to explore their legal rights and options,' he articulated.
Key Dates and Information for Investors
Investors should be aware of the timeline and important facts related to the lawsuit:
- Company: MoonLake Immunotherapeutics (MLTX)
- Class Period: March 10, 2024, to September 29, 2025
- Lead Plaintiff Deadline: December 15, 2025
- Significant Stock Drop: The stock price plummeted from $61.99 to a mere $6.24 after the VELA-2 trial failed to meet its primary endpoint.
What Should Investors Do Next?
For those who purchased shares of MoonLake between March 10, 2024, and September 29, 2025, and believe they have suffered losses, it is highly recommended to consult with Hagens Berman. The firm offers an opportunity for investors to understand their legal position and discuss the potential for being designated as a Lead Plaintiff in this class action lawsuit.
Take Action for Your Claim
Investors are encouraged to take initiative regarding their financial stake. The submission process for losses related to MoonLake is straightforward, and those interested should act promptly to ensure their claims are evaluated.
Frequently Asked Questions
What is the deadline for submitting claims related to MoonLake?
The deadline for submitting claims is December 15, 2025.
What led to the stock price drop for MoonLake?
The stock price fell dramatically due to disappointing results from the VELA-2 trial, which purportedly demonstrated the drug's ineffectiveness compared to competitors.
How can I contact Hagens Berman to discuss my losses?
Interested investors should reach out directly to Hagens Berman for guidance on their legal options related to the class action.
What is the significance of being a Lead Plaintiff?
A Lead Plaintiff represents the interest of all investors in a class action case, which can lead to greater involvement and potential compensation.
Are there protections for whistleblowers in this case?
Yes, whistleblowers with non-public information regarding MoonLake are encouraged to share their insights, potentially earning rewards through the SEC Whistleblower program.
